Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
| Revenue (Most Recent Fiscal Year) | $154.90M |
| Net Income (Most Recent Fiscal Year) | $-20.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -22.52% |
| Net Margin (Trailing 12 Months) | -22.52% |
| Return on Equity (Trailing 12 Months) | -293.02% |
| Return on Assets (Trailing 12 Months) | -10.00% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 24.35 |
| Inventory Turnover (Trailing 12 Months) | 0.52 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.03 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.19 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 189.85M |
| Free Float | 178.27M |
| Market Capitalization | $59.78M |
| Average Volume (Last 20 Days) | 2.92M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |